Atlas Trials

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT04657302 · COMPLETED

Trial details

NCT number
NCT04657302
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma
Start date
2021-01-08
Primary completion
2022-10-25
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.